Study: Omicron evades some but not all monoclonal antibodies

Several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the omicron variant now sweeping across the United States, researchers reported Jan. 19 in the journal Nature Medicine.

Why the Omicron BA.5 Variant Evades Vaccines

SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein–ACE2 complex

Omicron evades roughly twice the number of SARS-CoV-2 neutralizing antibodies than Delta

Interaction Analysis of the Spike Protein of Delta and Omicron Variants of SARS-CoV-2 with hACE2 and Eight Monoclonal Antibodies Using the Fragment Molecular Orbital Method

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2

Deep learning guided optimization of human antibody against SARS-CoV-2 variants with broad neutralization

Newest Omicron subvariants can evade boosters, antibody therapies

FDA Limits Use of Monoclonal Antibodies to Treat COVID-19

Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers

COVID-19 breakthrough infections and the omicron variant: What to know now

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization